The company said increases in comparable restaurant sales were offset by a decline in revenue from 45 permanent company-owned closures and by lowerFranchiserevenue from 10 franchise restaurant closures over the last twelve months. System-wide comparable restaurant sales increased 9.5%, comprising a 10.7% increase at …
Hardware revenues were US$12,404, versus US$363,642, and the company said new orders in the quarter were primarily software-only. Service, maintenance and other revenues decreased 27% to US$195,128 from US$268,113. Revenue from the Europe, Middle East and South America region increased 39% to US$924,760, and …
Research and development expense was US$5,542,281, versus US$4,584,131, which the company tied to its NEXICART-2 clinical trial and other CAR-T clinical andManufacturingactivities. It noted that no CIRM grant reimbursements were received in the quarter, compared with approximately US$1.1 million a year earlier, which had …
General and administrative expenses were US$5,859 thousand, versus US$6,433 thousand. The company tied the decrease primarily to a US$0.7 million decrease in stock-based compensation. Total operating expenses were US$14,477 thousand versus US$9,803 thousand, and the loss from operations equaled those amounts.
The company tied the HCC trial increase to changes in total trial costs from trial scope changes, and the TTI-109 decrease to higher costs in the third quarter of 2025 when its healthy volunteer study began. General and administrative expenses were US$1,854 thousand, versus …
Subscription revenue was US$3.6 million, versus US$1.5 million. The company said it ended the quarter with more than 142,000 paying Owlet360 subscribers. Revenue for the nine months was US$86.7 million, versus US$79.6 million.
The net loss before noncontrolling interest and preferred dividends was approximately US$13 million, versus US$6 million a year earlier. Net loss attributable to PAVM common stockholders was US$11.8 million, which management said remains subject to the finalDebtvaluation analysis. The non-GAAP adjusted loss was US$1.2 …
Net loss was US$6.4 million, or US$(0.42) per share, versus US$6.6 million, or US$(0.62) per share, a year earlier. Adjusted EBITDA, a non-GAAP measure, was US$(5.5) million, versus US$(6.0) million. For the nine months ended September 30, net product revenue was US$31.2 million, up …
Research and development expenses were US$4,219 thousand versus US$1,203 thousand, an increase of US$3.0 million that the company attributed to Phase 3 drug manufacturing costs and continuation of the Phase 2 clinical trial of stenoparib. A one-time expense of US$3.2 million for manufacturing of …
The company's common stock is listed on the New York Stock Exchange. The report was signed by Chief Executive Officer Maria Maccecchini.